NovoCure Ltd NVCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
Novocure's Premarket Application for Brain Metastases Treatment Otpune Mya Rejected by FDA
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure to Report Third Quarter 2026 Financial Results
Novocure Announces Upcoming Investor Events
Trading Information
- Previous Close Price
- $11.30
- Day Range
- $11.05–11.51
- 52-Week Range
- $9.82–21.45
- Bid/Ask
- $11.00 / $11.37
- Shares Outstanding
- 116.92M
- Market Cap
- $1.30B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,605
- Website
- https://www.novocure.com
Valuation
Metric | NVCR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.71 |
Price/Sales | 1.76 |
Price/Cash Flow | 223.92 |
Price/Earnings
NVCR
Financial Strength
Metric | NVCR |
|---|---|
Quick Ratio | 2.30 |
Current Ratio | 2.49 |
Interest Coverage | −3.71 |
Quick Ratio
NVCR
Profitability
Metric | NVCR |
|---|---|
Return on Assets (Normalized) | −0.86% |
Return on Equity (Normalized) | −2.33% |
Return on Invested Capital (Normalized) | 2.60% |
Return on Assets
NVCR
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|ZZVS?^J | LOCK|!Tr@ | $181B | |||
| Medtronic PLC MDT | LOCK|%$zn>Z | LOCK|^Kt% | $131B | |||
| Stryker Corp SYK | LOCK|#>!$ysC& | LOCK|$P | $121B | |||
| Boston Scientific Corp BSX | LOCK|$t%HSD | LOCK|Z>&bm | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|brV#s!s | LOCK|<Q%ZX | $61B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|<^>#$Ns | LOCK|YD | $37B | |||
| DexCom Inc DXCM | LOCK|?BHlW@? | LOCK|QyV^ | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|?V | LOCK|Z>$ | $29B | |||
| Steris PLC STE | LOCK|?ff?!% | LOCK|P$<c | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|<Xjn^$# | LOCK|%V& | $19B |